Stockscreener 앱 받기
20.76
10.54%
1.98
시장 영업 전:
21.05
0.29
+1.40%
전일 마감가:
$18.78
열려 있는:
$18.78
하루 거래량:
34.39M
Relative Volume:
1.08
시가총액:
$4.73B
수익:
$2.35B
순이익/손실:
$128.37M
주가수익비율:
39.76
EPS:
0.5221
순현금흐름:
$57.42M
1주 성능:
-2.72%
1개월 성능:
+42.98%
6개월 성능:
-63.40%
1년 성능:
-29.75%
1일 변동 폭
$18.64
$21.00
1주일 범위
$18.62
$22.00
52주 변동 폭
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
20.76 | 4.73B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.52 | 58.51B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.21 | 49.90B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
10.01 | 44.64B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.12 | 35.08B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
592.98 | 25.99B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2026-03-10 | 업그레이드 | Citigroup | Sell → Neutral |
| 2026-03-09 | 업그레이드 | Needham | Hold → Buy |
| 2026-02-24 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2026-01-12 | 개시 | Evercore ISI | In-line |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-21 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-04 | 재확인 | Needham | Buy |
| 2025-04-29 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Novo Partnership Fuels Long-Term Optimism for Hims & Hers Health, Inc. (HIMS) - Insider Monkey
Hims & Hers Broadens Tailored Online Health Services Platform - Bitget
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan - Benzinga
Hims & Hers Health Inc (HIMS) Stock Price Up 6.42% on Mar 31 - GuruFocus
Hims & Hers Expands Personalized Digital Healthcare Platform - TradingView
HIMS Gains as FDA Revisits Rules on Compounding Pharmacies - GuruFocus
HIMS Stock Gains As FDA Reportedly Moves Toward Lifting Restrictions On Peptides - Stocktwits
Hims Novo Nordisk GLP-1 Launch Ties Growth Story To Valuation Gap - simplywall.st
Hims & Hers Health, Inc. (HIMS) registers a bigger fall than the market: Important facts to note - MSN
HIMS Sees Moderate Bearish Sentiment Among Option Traders - GuruFocus
Hims & Hers Health, Inc. (HIMS) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Australia
Hims & Hers Health Options Spot-On: On March 30th, 88,151 Contracts Were Traded, With 1.15 Million Open Interest - Moomoo
HIMS stock in spotlight after Hims & Hers adds Novo’s GLP-1 treatments to its platform - MSN
Why (HIMS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Hims & Hers Health stock price forecast: persistent bearish setup as HIMS extends decline toward $18 - Traders Union
SG Americas Securities LLC Boosts Stock Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers Health Options Spot-On: On March 27th, 145.81K Contracts Were Traded, With 1.12 Million Open Interest - Moomoo
Barclays raises PT on Hims & Hers Health (HIMS) stock - MSN
Hims & Hers Stock Decline Amid Legal Battles and Strategic Repositioning - StocksToTrade
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know - Yahoo Finance
TD Cowen Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price - MarketBeat
Hims & Hers Health Launches Offering Featuring Novo Nordisk Products - marketscreener.com
From Breaking Stigma to Building the Future of Health - Hims & Hers Newsroom
Hims & Hers Health | SCHEDULE 13G/A: Others - Moomoo
Hims & Hers expands integrated digital healthcare ecosystem - msn.com
Hims & Hers: The Reset Before The Next Inflection (NYSE:HIMS) - Seeking Alpha
Vanguard (HIMS) reports 0 shares after internal realignment — Schedule 13G/A - Stock Titan
Hims & Hers Health (HIMS) price target decreased by 14.58% to 25.63 - MSN
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Canaccord reiterates Hims and Hers stock rating on Novo launch - Investing.com
Canaccord reiterates Hims and Hers stock rating on Novo launch By Investing.com - Investing.com India
HIMS Forecast, Price Target & Analyst Ratings | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Oil Surge Past $100, S&P 500 Changes & AI Trends | Market AnalysisNews and Statistics - IndexBox
Hims & Hers shifts business model after Novo deal - thestreet.com
Hims and Hers stock price target maintained at $23 by BofA Securities - Investing.com South Africa
What's Happening With Novo Nordisk Stock Today? - Benzinga
Hims & Hers Health (HIMS) Expands Offerings with Novo Nordisk Me - GuruFocus
-3.50% for Hims & Hers Health stock as daily low tests immediate support - Traders Union
Hims & Hers Health starts selling Novo Nordisk's Wegovy, Ozempic - Seeking Alpha
Why is Hims & Hers Health stock down today? - Traders Union
Hims & Hers adds Novo Nordisk GLP-1 medications to platform - Investing.com
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers - HIMS Investor Relations
Wegovy® Pill and Wegovy® Pen Now Available with Hims & Hers - Hims & Hers Newsroom
It’s Easier Than Ever To Get A Prescription Online. That Might Be A Problem - MedShadow Foundation
HIMS Stock In Spotlight After Hims & Hers Adds Novo’s GLP-1 Treatments To Its Platform - Stocktwits
Hims & Hers Health Options Spot-On: On March 25th, 136.26K Contracts Were Traded, With 1.06 Million Open Interest - Moomoo
Hims & Hers: Distressed Valuations Will Not Last For Long (NYSE:HIMS) - Seeking Alpha
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now? - TradingView
With Legal Overhang Behind, Hims Looks To Drive Growth via Novo Partnership and International Push - Morningstar
Hims & Hers Health stock slips 3.33% as resistance holds and sellers dominate near $20.00 support - Traders Union
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.90%
자본화:
|
볼륨(24시간):